nps-568 has been researched along with Hypercalcemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, Y; Ji, W; Lei, Z; Shi, N; Yu, L; Zhang, X | 1 |
| Bähr, V; Bumke-Vogt, C; Frank-Raue, K; Haag, C; Mayr, B; Möhlig, M; Raue, F; Rus, R; Schöfl, C; Schulze, E | 1 |
| Christopoulos, A; Gnacadja, G; Lu, JY; Reagan, JD; Yang, Y | 1 |
| Dikow, R; Gross, ML; Ritz, E | 1 |
| Fujita, T; Hashimoto, M; Iiri, T; Makita, N; Manaka, K; Oishi, A; Sato, J; Shoji, Y | 1 |
| Sugimoto, T | 1 |
| Ritz, E; Schömig, M | 1 |
3 review(s) available for nps-568 and Hypercalcemia
| Article | Year |
|---|---|
Role of calcium-phosphorous disorders in the progression of renal failure.
Topics: Aniline Compounds; Animals; Calcitriol; Calcium; Chronic Disease; Disease Progression; Fibroblast Growth Factor-23; Humans; Hypercalcemia; Hyperthyroidism; Kidney; Kidney Diseases; Kidney Failure, Chronic; Mesangial Cells; Parathyroid Hormone; Parathyroidectomy; Phenethylamines; Phosphates; Podocytes; Propylamines; Vitamin D | 2005 |
[Physiopathology and therapy of primary hyperparathyroidism].
Topics: Aniline Compounds; Humans; Hypercalcemia; Hyperparathyroidism; Parathyroidectomy; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 1999 |
Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives--calcimimetics.
Topics: Aniline Compounds; Animals; Calcitonin; Calcium; Calcium-Binding Proteins; Humans; Hypercalcemia; Hypocalcemia; Parathyroid Hormone; Phenethylamines; Propylamines; Treatment Outcome; Uremia; Vitamin D | 2000 |
4 other study(ies) available for nps-568 and Hypercalcemia
| Article | Year |
|---|---|
Radiofrequency Ablation of Parathyroid Glands to Treat a Patient With Hypercalcemia Caused by a Novel Inactivating Mutation in
Topics: Adult; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; HEK293 Cells; Humans; Hypercalcemia; Male; Mutation; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Radiofrequency Ablation; Receptors, Calcium-Sensing; Treatment Failure | 2021 |
Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors.
Topics: Aniline Compounds; Blotting, Western; Calcium; Cell Line; Humans; Hypercalcemia; Hypoparathyroidism; Mutagenesis, Site-Directed; Mutation; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Signal Transduction | 2008 |
Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.
Topics: Algorithms; Allosteric Regulation; Aniline Compounds; Animals; Calcium; Cell Line; Cricetinae; Cricetulus; Humans; Hypercalcemia; Hyperparathyroidism; Inositol Phosphates; Models, Biological; Mutation; Phenethylamines; Plasmids; Propylamines; Receptors, Calcium-Sensing; Transfection | 2009 |
An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations.
Topics: Aged; Allosteric Site; Aniline Compounds; Autoantibodies; Calcium; Cell Line; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Male; Parathyroid Hormone; Phenethylamines; Propylamines; Protein Conformation; Receptors, Calcium-Sensing; Signal Transduction | 2007 |